Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 43.2%, EPS fell 272.7% and free cash flow fell 184.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow KRSA
Korsana Biosciences, Inc. (KRSA) EV/Sales
As of 16 October 2026, Korsana Biosciences, Inc. (KRSA) trades at a EV/Sales of 8.8×. Over the past ten years it has ranged from −5.4× (November 2023) to 78.0× (June 2021); the current reading is higher than 76% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.4× | (87.44%) |
| FY2024 | 3.1× | (83.80%) |
| FY2022 | 19.0× | 459.05% |
| FY2021 | 3.4× | (79.82%) |
| FY2020 | 16.8× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 0.4× | (61.33%) |
| Sep 2025 | 1.0× | (63.39%) |
| Jun 2025 | 2.7× | 34.87% |
| Mar 2025 | 2.0× | (34.21%) |
| 16 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MAZE Maze Therapeutics, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | 1.7× |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 2.5× |
| KRSA Korsana Biosciences, Inc. | 8.8× |
| NTLA Intellia Therapeutics, Inc. compare | 18.3× |
| QURE uniQure N.V. compare | 36.8× |
| STOK Stoke Therapeutics, Inc. compare | 47.2× |
| ABSI Absci Corporation compare | 704× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)